Technical Analysis for CTXR - Citius Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 1.33 -3.62% -0.05
CTXR closed down 3.62 percent on Monday, May 20, 2019, on 1.34 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical CTXR trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
200 DMA Support Bullish 0.00%
Spinning Top Other 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 200 DMA Bullish -3.62%
MACD Bullish Centerline Cross Bullish -3.62%

Older signals for CTXR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.
Medicine Medical Specialties Pharmaceutical Drugs Catheter Cancer Care Care Products Prescription Products Acetamides Lidocaine
Is CTXR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.15
52 Week Low 0.8582
Average Volume 199,792
200-Day Moving Average 1.309
50-Day Moving Average 1.237
20-Day Moving Average 1.1248
10-Day Moving Average 1.182
Average True Range 0.1154
ADX 22.57
+DI 30.0006
-DI 8.4876
Chandelier Exit (Long, 3 ATRs ) 1.1538
Chandelier Exit (Short, 3 ATRs ) 1.2462
Upper Bollinger Band 1.3224
Lower Bollinger Band 0.9272
Percent B (%b) 1.02
BandWidth 35.135135
MACD Line 0.0278
MACD Signal Line -0.0092
MACD Histogram 0.037
Fundamentals Value
Market Cap 10.97 Million
Num Shares 8.25 Million
EPS -1.98
Price-to-Earnings (P/E) Ratio -0.67
Price-to-Sales 0.00
Price-to-Book 1.16
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.67
Resistance 3 (R3) 1.68 1.58 1.61
Resistance 2 (R2) 1.58 1.49 1.57 1.59
Resistance 1 (R1) 1.45 1.44 1.40 1.44 1.57
Pivot Point 1.35 1.35 1.33 1.35 1.35
Support 1 (S1) 1.23 1.27 1.18 1.22 1.09
Support 2 (S2) 1.13 1.21 1.12 1.07
Support 3 (S3) 1.00 1.13 1.05
Support 4 (S4) 0.99